Cambiogenplasmid: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 2: | Line 2: | ||
{{stb}} | {{stb}} | ||
{{short-articles-ni}} | {{short-articles-ni}} | ||
{{No image}} | |||
Latest revision as of 09:25, 10 February 2025
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. It was developed by the in Russia and approved in Russia in 2011
| This article is a stub. You can help WikiMD by registering to expand it. |
